Also known as 1,10-bis(guanidino)decane, decamethylenediguanidine, 1,1'-decamethylenediguanidine, decamethylenebis(guanidine), N,N'''-1,10-Decanediylbisguanidine
Synthalin was an oral anti-diabetic drug. Discovered in 1926 it was marketed in Europe by Schering AG of Berlin as a synthetic drug with insulin-like properties that could be taken orally. However, it was toxic to the liver and kidney and was withdrawn from the market in the early 1940s.
~2 min read
Synthalin was an oral anti-diabetic drug. Discovered in 1926 it was marketed in Europe by Schering AG of Berlin as a synthetic drug with insulin-like properties that could be taken orally. However, it was toxic to the liver and kidney and was withdrawn from the market in the early 1940s.
==History== The folk remedy French lilac (Galega officinalis), was used to treat the symptoms of diabetes, and towards the end of the nineteenth century it was discovered to contain galegine, a derivative of guanidine. This had a hypoglycaemic effect but was very toxic to the liver. Karl Slotta at the Chemistry Institute of the University of Vienna synthesized derived compounds that had a polymethylene chain with a guanidine group at each end. These diguanides were less toxic and more potent than guanidine. In 1926, E. Frank, working in Oskar Minkowski's clinic in Wroclaw performed a clinical trial on one of these agents. It was subsequently marketed as Synthalin by Schering AG for treating mild cases of diabetes.
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).